CIBA EFIDAC/24 AD CLAIMS FOUND SUBSTANTIATED BY NAD
This article was originally published in The Tan Sheet
Executive Summary
CIBA EFIDAC/24 AD CLAIMS FOUND SUBSTANTIATED BY NAD following an inquiry into print and TV advertising for the extended relief pseudoephedrine-based cold product. The National Advertising Division of the Council of Better Business Bureaus announced Jan. 11 that, based on a review of data supplied by Ciba Consumer, several "explicit" claims were determined to be substantiated, including: "The first cold tablet for consistent 24-hour relief"; "Look, Sudafed drops off after six hours, Tavist-D after 12..."; and "...but just one Efidac gives consistent relief for 24 hours."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning